

1 **Unidirectional and Bidirectional Causation between Smoking and Blood DNA** 2 **Methylation: Evidence from Twin-based Mendelian Randomisation**

3

4 Running head: **Causation between smoking and DNA methylation**

5

6 Madhurbain Singh^{1,2,3*}, Conor V. Dolan^{3,4,11}, Dana M. Lapato^{1,2}, Jouke-Jan Hottenga^{3,4}, René
7 Pool^{3,4}, Brad Verhulst⁵, Dorret I. Boomsma^{3,4,12}, Charles E. Breeze^{6,7}, Eco J. C. de Geus^{3,4},
8 Gibran Hemani⁸, Josine L. Min⁸, Roseann E. Peterson^{9,10,1}, Hermine H. M. Maes^{1,2}, Jenny van
9 Dongen^{3,4,11*} and Michael C. Neale^{1,2,3,11*}

10

- 11 1. Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry,
12 Virginia Commonwealth University, Richmond, VA, USA
- 13 2. Department of Human and Molecular Genetics, Virginia Commonwealth University,
14 Richmond, VA, USA
- 15 3. Department of Biological Psychology, Vrije Universiteit (VU) Amsterdam, Amsterdam,
16 The Netherlands
- 17 4. Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
- 18 5. Department of Psychiatry and Behavioral Sciences, Texas A&M University, College
19 Station, TX, USA
- 20 6. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National
21 Institutes of Health, Department Health and Human Services, Bethesda, MD, USA
- 22 7. UCL Cancer Institute, University College London, London, UK.
- 23 8. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
- 24 9. Department of Psychiatry and Behavioral Sciences, SUNY Downstate Health Sciences
25 University, Brooklyn, NY, USA
- 26 10. Institute for Genomics in Health, SUNY Downstate Health Sciences University,
27 Brooklyn, NY, USA
- 28
- 29 11. These authors jointly supervised this work.
- 30 12. Current address: Department of Complex Trait Genetics, Center for Neurogenomics and
31 Cognitive Research, Vrije Universiteit (VU) Amsterdam, Amsterdam, The Netherlands

32

33 *Corresponding authors:

34 Madhurbain Singh. Email: singhm18@vcu.edu. Address: Virginia Institute for Psychiatric and
35 Behavioral Genetics, 800 E. Leigh St., Suite 100, Richmond, VA 23298, USA

36 Jenny van Dongen. Email: j.van.dongen@vu.nl. Address: Department of Biological Psychology,
37 Vrije Universiteit Amsterdam, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands

38 Michael C. Neale. Email: michael.neale@vcuhealth.org. Address: Virginia Institute for
39 Psychiatric and Behavioral Genetics, 800 E. Leigh St., Suite 100, Richmond, VA 23298, USA

40

41 **ORCID**

42 Madhurbain Singh: 0000-0002-9396-2860
43 Conor V. Dolan: 0000-0002-2496-8492
44 Dana M. Lapato: 0000-0001-8169-9754
45 Jouke-Jan Hottenga: 0000-0002-5668-2368
46 René Pool: 0000-0001-5579-0933
47 Brad Verhulst: 0000-0001-5369-9757
48 Dorret I. Boomsma: 0000-0002-7099-7972
49 Charles E. Breeze: 0000-0002-5294-915X
50 Eco J. C. de Geus: 0000-0001-6022-2666
51 Gibran Hemani: 0000-0003-0920-1055
52 Josine L. Min: 0000-0003-4456-9824
53 Roseann E. Peterson: 0000-0001-6402-849X
54 Hermine H. M. Maes: 0000-0001-7489-2214
55 Jenny van Dongen: 0000-0003-2063-8741
56 Michael C. Neale: 0000-0003-4887-659X

57 **Funding**

58 We acknowledge funding from the U.S. National Institute on Drug Abuse grant R01DA049867,
59 the Netherlands Organization for Scientific Research (NWO): Biobanking and Biomolecular
60 Research Infrastructure (BBMRI-NL, NWO 184.033.111) and the BBRMI-NL-financed BIOS
61 Consortium (NWO 184.021.007), NWO Large Scale infrastructures X-Omics (184.034.019),
62 Genotype/phenotype database for behaviour genetic and genetic epidemiological studies
63 (ZonMw Middelgroot 911-09-032); Netherlands Twin Registry Repository: researching the
64 interplay between genome and environment (NWO-Groot 480-15-001/674); the Avera Institute,
65 Sioux Falls (USA), and the U.S. National Institutes of Health (NIH R01HD042157-01A1,
66 R01MH081802, R01MH125938, and Grand Opportunity grants 1RC2 MH089951 and 1RC2
67 MH089995). DML is supported by the NIH K01MH131847. DIB acknowledges the Royal
68 Netherlands Academy of Science Professor Award (PAH/6635). JLM and GH are supported by
69 the UK Medical Research Council (MRC) Integrative Epidemiology Unit at the University of
70 Bristol (MC_UU_00011/1, MC_UU_00011/5).

71 **Acknowledgements**

72 NTR warmly thanks all participants. Epigenetic data were generated at the Human Genomics
73 Facility (HuGe-F) at ErasmusMC Rotterdam (<http://www.glimdna.org/>) as part of the Biobank-
74 based Integrative Omics Study Consortium. We thank Dr. Scott Vrieze (University of
75 Minnesota) for providing the leave-one-out GWAS summary statistics from the GWAS &
76 Sequencing Consortium of Alcohol and Nicotine Use (GSCAN).

77 **Conflicts of Interest**

78 Nothing to declare.

79 **Data Availability**

80 Data from the Netherlands Twin Register (NTR) may be accessed for research purposes by
81 submitting a data-sharing request. Further information about NTR data access is available at
82 <https://ntr-data-request.psy.vu.nl/>.

83 Results of all MR-DoC models fitted in this study are available as Supplementary Data on OSF
84 (doi:10.17605/OSF.IO/R6HVY).

85 **Code Availability**

86 The code used in the analyses for this study is available at: [https://github.com/singh-](https://github.com/singh-madhur/MRDOC_Smoking_DNA_m_NTR)
87 [madhur/MRDOC_Smoking_DNA_m_NTR](https://github.com/singh-madhur/MRDOC_Smoking_DNA_m_NTR).

88

89

Abstract

90 Cigarette smoking is associated with numerous differentially-methylated genomic loci in
91 multiple human tissues. These associations are often assumed to reflect the causal effects of
92 smoking on DNA methylation (DNAm), which may underpin some of the adverse health
93 sequelae of smoking. However, prior causal analyses with Mendelian Randomisation (MR) have
94 found limited support for such effects. Here, we apply an integrated approach combining MR
95 with twin causal models to examine causality between smoking and blood DNAm in the
96 Netherlands Twin Register (N=2577). Analyses revealed potential causal effects of current
97 smoking on DNAm at >500 sites in/near genes enriched for functional pathways relevant to
98 known biological effects of smoking (e.g., hemopoiesis, cell- and neuro-development, and
99 immune regulation). Notably, we also found evidence of reverse and bidirectional causation at
100 several DNAm sites, suggesting that variation in DNAm at these sites may influence smoking
101 liability. Seventeen of the loci with putative effects of DNAm on smoking showed highly
102 specific enrichment for gene-regulatory functional elements in the brain, while the top three sites
103 annotated to genes involved in G protein-coupled receptor signalling and innate immune
104 response. These novel findings are partly attributable to the analyses of *current* smoking in twin
105 models, rather than *lifetime* smoking typically examined in MR studies, as well as the increased
106 statistical power achieved using multiallelic/polygenic scores as instrumental variables while
107 controlling for potential horizontal pleiotropy. This study highlights the value of twin studies
108 with genotypic and DNAm data for investigating causal relationships of DNAm with health and
109 disease.

110

111 **Keywords**

112 Smoking, DNA Methylation, Causal inference, Twin modelling, Mendelian Randomisation,
113 Epigenetics

114

115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151

Introduction

Epigenome-wide association studies (EWASs) identify variation in DNA methylation (DNAm) associated with complex human traits and diseases [1]. Arguably, the most successful EWASs have been studies of cigarette smoking. A large-scale EWAS meta-analysis of current versus never smoking revealed significant DNAm differences at 18,760 CpG (*Cytosine-phosphate-Guanine*) sites in peripheral blood cells [2]. DNAm differences between former- and never-smoking individuals were diminished but remained significant at 2,568 sites. Genes annotated to the differentially methylated CpGs have been implicated in genome-wide association studies (GWAS) of numerous smoking-associated traits, including cancers, lung functions, cardiovascular disorders, inflammatory disorders, and schizophrenia [2].

As standard cross-sectional EWAS in unrelated individuals cannot differentiate between causation and confounding [3], different etiological mechanisms may underlie the associations between cigarette smoking and DNAm. These associations are typically interpreted as the causal *effects* of smoking exposure on DNAm. However, some smoking-associated CpGs may have reverse or bidirectional causal links with smoking, i.e., DNAm may reciprocally affect the development and maintenance of smoking behaviours [4]. Moreover, associations between smoking and DNAm may be attributable to confounders, such as schizophrenia [5], alcohol [6] and cannabis use [7] and body mass index [8].

Mendelian Randomisation (MR) analyses use genetic variants as instrumental variables (IVs) to estimate causal effects [3,9]. MR analyses have identified the effects of lifetime (current or former) smoking on blood DNAm at only 11 CpGs [10], with reverse effects of blood DNAm at nine sites [11]. Causal inference in MR is based on the assumption that the genetic variants associated with the exposure influence the outcome exclusively through the exposure.



Specifically, genetic IVs for smoking may show vertical, but not horizontal, pleiotropy with DNAm. To minimise the risk of horizontal pleiotropy, MR analyses require carefully selected single-nucleotide polymorphisms (SNPs), including using genetic colocalisation to filter out SNPs showing horizontal pleiotropy due to linkage disequilibrium (LD). Since SNPs usually have small effect sizes, traditional MR approaches may have limited power to detect causality and may be subject to weak-instrument bias [12]. Furthermore, causal inference in standard, summary-statistics-based MR analyses typically applies to the GWAS phenotype of *lifetime* smoking. However, as most smoking-associated DNAm changes exhibit substantial reversibility upon smoking cessation [2,13], it is important to examine the causal relationships of *current* smoking specifically.

152 Recent methodological developments integrate the principles of MR with the twin-based
153 *Direction of Causation* (DOC) model [14], giving rise to the unidirectional *MR-DoC1* [15] and
154 the bidirectional *MR-DoC2* models [16]. MR-DoC1 allows one to estimate and account for
155 horizontal pleiotropy, while MR-DoC2 accommodates pleiotropy arising from LD. Thus, these
156 models enable using polygenic risk scores (PRS) as IVs, increasing the statistical power to
157 estimate causal effects and curtailing weak-instrument bias, relative to MR methods using
158 individual SNPs as IVs. Incorporating MR with family data also helps to resolve additional
159 assumptions of standard MR, such as random mating and no dyadic effects [15,17]. Moreover,
160 by using participant-level information, these models estimate causal effects between the
161 phenotypes measured in the twins, allowing separate causal models for current and former
162 smoking.

163
164 The present study used MR-DoC models to examine bidirectional causal effects between
165 cigarette smoking and peripheral blood DNAm in a population-based cohort of European
166 ancestry adult twins from the Netherlands Twin Register (NTR) [18,19]. The target sample
167 included 2,577 individuals from 1,459 twin pairs with both genotypic and DNAm data, and self-
168 reported smoking status at the time of blood draw. Across 16,940 smoking-related CpGs, we
169 fitted separate models for current (versus never) and former (versus never) smoking. We
170 obtained a set of three causal estimates in each direction (*Smoking* \rightarrow *DNAm*, *DNAm* \rightarrow
171 *Smoking*): the estimates from bidirectional MR-DoC2, and two different model specifications of
172 unidirectional MR-DoC1 (**Figure 1**). We triangulated evidence across the three models based on
173 the statistical significance and consistency of the causal estimates. The results indicated much
174 more widespread putative causal influences of current smoking on DNAm than *vice versa*.
175 Follow-up enrichment analyses highlighted biological processes and tissues relevant to the CpGs
176 with potential effects in either direction of causation.

177

178



180
181
182
183
184
185
186
187
188
189
190
191
192

Figure 1. Study Design.

Overview of the data and MR-DoC models used to examine the causality between cigarette smoking and blood DNA methylation (DNAm) in the Netherlands Twin Register. The models were fitted separately for current (versus never) and former (versus never) smoking. Applying the five MR-DoC models shown in the path diagrams, we obtained a set of three causal estimates in each direction of causation: Smoking (Smk) → DNAm (the blue paths labelled g_1) and DNAm → Smoking (the red paths labelled g_2).

*In each MR-DOC model, the residual variance of each phenotype (smoking status liability and DNAm levels) is decomposed into latent additive genetic (A) and unique environmental (E) factors. The correlation between the latent A factors of smoking and DNAm (r_A) represents confounding due to additive genetic factors, while that between the latent E factors (r_E) represents confounding due to unique environmental factors. Note that these models did not include shared environmental (C) variance components, as the AE model was found to be the most parsimonious in univariate twin models (see **Supplementary Methods**).*

Note. For better readability, the path diagrams show only the within-individual part of the models fitted to data from twin pairs. The squares/rectangles indicate observed variables, the circles indicate latent (unobserved) variables, the single-headed arrows indicate regression paths, and the double-headed curved arrows indicate (co-)variances.

193

Methods

194 Study Sample

195 We analysed data from 706 monozygotic (MZ) twin pairs, 412 dizygotic (DZ) twin pairs, and
196 341 individuals without their co-twin. The participants, 1,730 (67%) females and 847 (33%)
197 males, were aged 18–79 (mean 35.2; S.D. 11.7 years) at the time of blood draw. Sample and
198 variant quality control (QC) of genotypic data, imputation, genetic principal component analysis
199 (PCA), and ancestry-outlier pruning have been described previously [20], and reviewed in
200 **Supplementary Methods**. Since the summary statistics of methylation quantitative trait loci
201 (mQTLs) were available for European ancestry only [21], we excluded 109 participants
202 identified as European-ancestry outliers to avoid bias due to ancestry mismatch.

203

204 The NTR is approved by the Central Ethics Committee on Research Involving Human Subjects
205 of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the
206 U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-wide
207 Assurance- FWA00017598; IRB/institute codes, NTR 98-222, 2003-180, 2008-244). All
208 participants provided written informed consent before data collection.


209 Peripheral Blood DNA Methylation and Cell Counts

210 Epigenome-wide DNAm in peripheral whole blood was measured with the Infinium
211 HumanMethylation450 BeadChip Kit (“Illumina 450k” microarray), following manufacturer’s
212 protocol [22]. DNAm data QC and normalisation were performed using a custom pipeline
213 developed by the BIOS (Biobank-based Integrative Omics Study) Consortium [23]
214 (**Supplementary Methods**). In the current analyses, only autosomal probes were included,
215 yielding 411,169 CpGs that passed QC, of which 16,940 sites were associated with current
216 smoking (FDR <0.05) in a previous independent EWAS [2] (hereafter called the “smoking-
217 associated CpGs”). These CpGs were analysed in the MR-DoC1 models for *Current Smoking* →
218 *DNAm* (**Figure 2**). Likewise, 2,330 autosomal, post-QC CpGs, previously associated with former
219 smoking [2] (hereafter called the “former-smoking-associated CpGs”), were analysed in the MR-
220 DoC1 models for *Former Smoking* → *DNAm*. Differential white blood cell counts were also
221 measured in the blood samples [23].

222

223 The normalised β -values of DNAm at each CpG were residualised by regressing out age, sex
224 (genotypically inferred biological sex, matched with self-reported sex), measured white blood
225 cell percentages (neutrophils, monocytes, and eosinophils), HM450k array row, and bisulfite
226 sample plate [24]. The residuals were standardised (mean = 0, S.D. = 1). As in the previous NTR

227 work [24], we excluded lymphocyte percentage as a covariate, given its multicollinearity with
228 neutrophil percentage. We excluded basophil percentage because of its low variance.
229



230

231 **Figure 2. Selection of CpGs tested in each MR-DoC model.**

232 *Previous independent EWAS meta-analysis of cigarette smoking [2] examined DNA methylation*
233 *(DNAm) at CpGs from the Illumina HumanMethylation450 BeadChip array [22], which was also*
234 *used to measure DNAm in the NTR biobank. In the unidirectional MR-DoC1 models for Smoking*

235 → DNAm, we included autosomal CpGs associated with smoking in the EWAS meta-analysis
236 that also passed the QC metrics in NTR. The MR-DoC1 models for DNAm → Smoking and the
237 bidirectional MR-DoC2 models were restricted to a subset of these sites having cis-mQTL
238 summary statistics from the GoDMC [21] and a resulting mQTL allelic score with F-statistic
239 >10.
240

241 **Cigarette Smoking**

242 Self-reported cigarette smoking status was recorded during blood sample collection in 2004-
243 2008 and 2010-2011 (**Supplementary Methods**), with the question, “Do you smoke?” with
244 three response options: “No, I never smoked” (N = 1,492), “No, but I did in the past” (N = 549),
245 and “Yes” (N = 528). The responses were checked for consistency with data from the
246 longitudinal NTR surveys and plasma cotinine levels (**Supplementary Methods**).

247 **Instrumental Variables**

248 **mQTL allelic scores.** We used a weighted sum of DNAm-increasing alleles at *cis*-mQTLs
249 (“mQTL allelic score”) as the IV for DNAm, computed using clumping and thresholding in
250 *PLINK1.9* [25] (**Supplementary Methods**). Of the 16,940 smoking-associated CpGs, 12,940
251 had summary statistics for *cis*-mQTLs available from the Genetics of DNA Methylation
252 Consortium (GoDMC; excluding NTR) [21] (**Figure 2**). We used only *cis*-mQTLs, i.e., SNPs
253 within 1Mb of the CpG, given that SNPs located close to the CpG are likely to be associated
254 with smoking *via* DNAm. To further guard against potential horizontal pleiotropy with smoking,
255 we relied on the consistency of the causal estimates in MR-DoC models accommodating
256 horizontal pleiotropy. To reduce the risk of weak-instrument bias, we restricted the MR-DoC1
257 models for *DNAm* \rightarrow *Current Smoking* and the bidirectional MR-DoC2 models to 11,124
258 (65.7%) CpGs having an mQTL allelic score with F-statistic >10 (**Figure 2**). The included
259 mQTL allelic scores had an incremental R^2 for the respective CpG site ranging from 0.43% to
260 76.95% (mean 9.04%, S.D. = 10.94%). Similarly, a subset of 1,782 (76.5%) former-smoking-
261 associated CpGs had mQTL allelic scores with F-statistic >10 and were examined in the MR-
262 DoC1 models for *DNAm* \rightarrow *Former Smoking* and the bidirectional model (MR-DoC2).

263
264 **PRS of Regular Smoking Initiation.** We used a PRS of lifetime regular-smoking initiation as the
265 IV for smoking status, computed using *LDpred v0.9* [26] with European-ancestry GWAS
266 summary statistics [27] (**Supplementary Methods**). This PRS had an incremental liability-scale
267 R^2 of 5.07% (F-statistic = 73.2) for current versus never smoking, and 2.02% (F-statistic = 28.8)
268 for former versus never smoking. The smoking phenotypes in MR-DoC models differed from the
269 GWAS phenotype (smoking initiation = current/former versus never smoking). However, in
270 these causal models, the strength of the IV, the extent of horizontal pleiotropy with DNAm, and
271 the estimated causal effects on DNAm apply to the smoking phenotype operationalised in the
272 target data.

273
274 We residualised the smoking PRS and all mQTL allelic scores for the genotyping platform and
275 the first ten genetic PCs, and standardised the residuals (mean = 0, S.D. = 1).

276 **MR-DoC Models**

277 Causal inference in twin data leverages the cross-twin cross-trait correlations to estimate the
278 direction and magnitude of potential causal effects between traits [14]. On the other hand, MR
279 analyses rely on the assumptions that the IV is (1) associated with the exposure (“relevance”), (2)
280 not correlated with any omitted confounding variables (“exchangeability”), and (3) independent
281 of the outcome, given the exposure (“exclusion restriction”) [3,28]. Here, we used the criterion
282 of F-statistic >10 to identify “relevant” IVs. Further, genetic variants are assumed to satisfy the
283 “exchangeability” assumption, given Mendel’s laws of random segregation and independent
284 assortment. The “exclusion restriction” assumption for a genetic IV implies no horizontal
285 pleiotropy with the outcome. Here, we applied different MR-DoC models (**Figure 1**) to account
286 for possible horizontal pleiotropy. MR-DoC1 accommodates horizontal pleiotropy under the
287 assumption of no confounding due to unique environmental factors. The alternative specification
288 of MR-DoC1 accommodates unique environmental confounding (parameter “rE” in **Figure 1**),
289 given the assumption of no horizontal pleiotropy [15]. In both cases, the model includes
290 confounding due to genetic and shared environmental influences on the exposure and the
291 outcome. In MR-DoC2 models, we estimated bidirectional causal effects by including the
292 smoking PRS and the mQTL allelic score, allowing the two IVs to covary [16]. Beyond the
293 causal effects between smoking and DNAm, the covariance between the PRS and the mQTL
294 allelic score may arise from several sources, including shared pleiotropic SNPs, LD between the
295 constituent SNPs, and population structure. By accommodating these sources of covariance, MR-
296 DoC2 may help reduce potential biases in the causal estimates.

297
298 The MR-DoC models were fitted in the *OpenMx* package (v2.21.8) [29] in R (v4.3.2), using the
299 code from the original publications [15,16] (**Supplementary Methods**). Binary smoking status
300 was examined in the liability threshold model [30], so the causal estimate is interpreted as the
301 effect of the underlying smoking *liability* rather than smoking *exposure*. Age and sex were
302 included in the model as covariates of smoking status. For each set of causal estimates across
303 CpGs (**Figure 1**), we calculated the Bayesian genomic inflation factor (λ) using the R package
304 *bacon* [31], made QQ plots using the R package *GWASTools* [32], and applied Benjamini-
305 Hochberg FDR correction [33] to the p-values.

306 **Functional Enrichment Analyses**

307 We used *Metascape* (v3.5.20240101) [34] to perform gene-set annotation and functional
308 enrichment analyses of the CpGs with potential causal effects in either direction
309 (**Supplementary Methods**). The input list of gene IDs was selected based on proximity to the
310 CpGs with consistent and nominally significant ($p < 0.05$) estimates in all three models.

311 Furthermore, to explore the tissue-specific functional relevance of the implicated CpGs, we
312 performed *eFORGE 2.0* (experimentally derived Functional element Overlap analysis of
313 ReGions from EWAS) analyses [35–37]. We examined the overlap between the implicated CpGs
314 and multiple comprehensive reference sets of tissue-/cell type-specific gene regulatory genomic
315 and epigenomic features, including chromatin states, histone marks, and DNase-I hotspots
316 **(Supplementary Methods)**.

317
318

319

320

Results

321 **Exemplar: Putative causality between current smoking and *AHRR* DNAm**

322 To illustrate the three MR-DoC models, we first present the results for two CpGs (cg23916896
323 and cg05575921) in the Aryl-Hydrocarbon Receptor Repressor (*AHRR*) gene, with well-
324 established DNAm associations with cigarette smoking [2].

325

326 For probe cg23916896 (**Supplement Figure S1A**), the mQTL allelic score had an incremental
327 R^2 of 8.03% (F-statistic = 156.4). The MR-DoC models indicated that higher liability for current
328 smoking likely causes hypomethylation of cg23916896, with statistically significant (FDR
329 <0.05), consistently negative causal estimates in all three models. The reverse effect of
330 cg23916896 methylation on the liability for current smoking had consistent negative estimates.
331 However, the estimates were significant at FDR <0.05 in MR-DoC1 with horizontal pleiotropy,
332 but only nominally significant ($p <0.05$) in the other two models. Taken together, these results
333 provide robust evidence for current smoking's causal effects on cg23916896 methylation, with
334 suggestive evidence for reverse causation. Previous MR studies have not examined this CpG site,
335 as these studies focused on a few pre-selected sites [10,11]. Our results indicate a potential
336 bidirectional causal relationship between cigarette smoking and cg23916896, i.e., smoking-
337 induced hypomethylation at this locus may reciprocally increase smoking liability.

338

339 In comparison, probe cg05575921 had an mQTL allelic score with an incremental R^2 of 1.74%
340 (F-statistic = 31.6). Similar to cg23916896, the effect of current smoking liability on
341 cg05575921 methylation was consistently negative, with FDR <0.05 in all three models
342 (**Supplement Figure S1B**). This aligns with the previously reported negative, albeit non-
343 significant, effect of *lifetime* smoking [10]. For the reverse effect of cg05575921 methylation on
344 smoking liability, the estimates were negative in all three models, though statistically significant
345 only in MR-DoC1 with horizontal pleiotropy. Notably, the estimates for cg05575921 are
346 comparable to those for cg23916896, but have larger standard errors, likely due to the weaker IV
347 of the former (mQTL allelic score). This variability in the precision of the causal estimates
348 underscores the differences in the strength of the IV across CpGs and, consequently, the power
349 to estimate their causal effect on smoking.

350


351 **Evidence of more widespread effects of current smoking on DNAm than *vice***
352 ***versa***

353 We used genomic inflation factor, λ , to evaluate potential widespread, small causal effects of
354 current smoking on DNAm. Across the smoking-associated CpGs, MR-DoC1 including
355 horizontal pleiotropy ($rE = 0$) had $\lambda = 1.44$, while MR-DoC1 with unique environmental
356 confounding, but no horizontal pleiotropy, showed $\lambda = 1.20$. For comparison, fitting similar
357 models epigenome-wide showed less inflation ($\lambda = 0.98$ and $\lambda = 1.09$, respectively), suggesting
358 enrichment of low p-values among the smoking-associated CpGs, as also reflected in the QQ
359 plots (**Supplementary Figures S2-S3**). The epigenome-wide inflation is consistent with that for
360 cigarettes per day ($\lambda > 1.1$), as seen in prior two-sample MR analyses [21]. In MR-DoC2 models,
361 the estimated reverse effects of DNAm on current smoking showed little inflation ($\lambda = 1.01$)
362 compared to current smoking's effects on DNAm in the same model ($\lambda = 1.20$; **Supplementary**
363 **Figures S4-S5**). These findings suggest that the causal influences of current smoking on DNAm
364 contribute partly to the previously reported EWAS hits. However, for the reverse effects of
365 DNAm on current smoking, the absence of λ inflation does not preclude potential localised small
366 effects, albeit at fewer CpGs.

367
368 There was considerable variability in the number of CpGs with statistically significant causal
369 estimates across models (**Figure 3; top panel**), with a relatively higher number of significant
370 estimates in MR-DoC1 with horizontal pleiotropy, likely due to its higher power [38]. Looking at
371 the intersection of significant *Current Smoking* \rightarrow *DNAm* estimates across models, 259 CpGs
372 showed FDR < 0.05 in at least two models, while 64 sites showed FDR < 0.05 in all three models.
373 These 64 sites also showed a consistent direction of effect in all models (**Supplementary Figure**
374 **S6, Table S1**). Thus, we considered these 64 CpGs to exhibit robust evidence for current
375 smoking's effects on DNAm, including hypomethylation of 59 sites and hypermethylation of the
376 other five (**Figure 3; bottom panel**). These CpGs annotate to several top genes implicated in
377 prior EWAS of smoking [2], including hypomethylation of CpGs in/near *AHRR*, *ALPPL2*,
378 *CNTNAP2*, and *PARD3* and hypermethylation of CpGs in *MYO1G*. Only one of these 64 CpGs
379 lies within the major histocompatibility complex (MHC) region: cg06126421 (near *HLA-DRB5*).
380 Due to its complex LD structure, the causal estimates of the sites in the MHC region should be
381 interpreted with caution.

382

Putative Causal Effects of Current Smoking on DNA Methylation in MR-DoC Models



383
384

385 **Figure 3. Putative Causal Effects of Current Smoking on Blood DNA Methylation in MR-**
386 **DoC Models**

387 *The top panel shows an UpSet plot of the intersection of CpGs with statistically significant (FDR*
388 *<0.05) estimates of Current Smoking → DNAm in the three MR-DoC models. The matrix*
389 *consists of the models along the three rows and their intersections along the columns. The*
390 *horizontal bars on the left represent the number of CpGs with significant (FDR <0.05) causal*
391 *estimates in each model. The vertical bars represent the number of CpGs belonging to the*
392 *respective intersection in the matrix. A similar UpSet plot with Bonferroni correction is shown in*
393 **Supplementary Figure S7.**

394 *The bottom panel shows a Miami plot of the Current Smoking → DNAm causal estimates across*
395 *16,940 smoking-associated CpGs. The X-axis shows the genomic positions of the CpGs aligned*
396 *to Genome Reference Consortium Human Build 37 (GRCh37). The Y-axis shows the Z-statistic*
397 *of the estimated effect of the liability for current (versus never) smoking on (residualised and*
398 *standardised) DNA methylation b-values in the MR-DoC1 model with unique environmental*
399 *confounding (rE). The solid points indicate the 64 sites with significant causal estimates (FDR*
400 *<0.05) in all three models (i.e., the blue vertical bar in the UpSet plot). The 14 CpGs with causal*
401 *estimates significant after Bonferroni correction in more than one model are labelled by their*
402 *respective nearest gene.*

403 *Note. The data underlying these plots are in **Supplementary Table S1.***

404 —

405

406

407 For *DNAm* → *Current Smoking*, 44 CpGs showed FDR <0.05 in at least two models, but only
408 three CpGs had FDR <0.05 in all models (**Figure 4B**). The three CpGs also had consistent,
409 positive estimates across models, suggesting that hypermethylation of CpGs in *GNG7*, *RGS3*,
410 and *SLC15A4* genes may increase smoking liability (**Figure 4A**). None of these sites has been
411 previously reported to influence smoking liability [11].


412 **Suggestive Evidence of Bidirectional Effects**

413 Of the 64 sites with robust evidence of *Current Smoking* → *DNAm* effects, three sites also had
414 consistently negative, nominally significant ($p < 0.05$) estimates of reverse *DNAm* → *Current*
415 *Smoking* effects (**Figure 4C**). The three CpGs (cg23916896, cg11902777, cg01899089) are
416 located in the *AHRR* gene, suggesting that current smoking may cause hypomethylation of CpGs
417 in *AHRR*, which may reciprocally increase smoking liability. Among the CpGs with robust
418 evidence of DNAm effects on current smoking, cg13078421 (*GNG7*) also showed consistently
419 positive, nominally significant estimates of current smoking's effects on DNAm. Thus, *GNG7*
420 hypermethylation increases smoking liability, with a potential reverse effect of current smoking
421 on *GNG7* methylation. Additionally, 15 CpGs had consistent, nominally significant bidirectional
422 causal estimates in all three models, though not significant after FDR correction in either
423 direction (**Supplementary Figure S9**).

424

425

Putative Reverse and Bidirectional Causal Effects of DNA Methylation on Current Smoking in MR-DoC Models



426

427 **Figure 4. Potential reverse and bidirectional effects of blood DNA methylation on current**
428 **smoking**

429 (A.) Estimates and Wald-type 95% confidence intervals of DNAm → Current Smoking causal
430 effects in each of the three MR-DoC models: bidirectional MR-DoC2, MR-DoC1 with horizontal
431 pleiotropic path, and MR-DoC1 with unique environmental confounding (rE). (B.) An UpSet plot
432 of the intersection of CpGs with statistically significant (FDR < 0.05) estimates of DNAm →

433 *Current Smoking in each of the three MR-DoC models. The matrix consists of the models along*
434 *the three rows and their intersections along the columns. The horizontal bars on the left*
435 *represent the number of CpGs with significant (FDR <0.05) causal estimates in each model. The*
436 *vertical bars represent the number of CpGs belonging to the respective intersection in the*
437 *matrix. A similar UpSet plot with Bonferroni correction is shown in **Supplementary Figure S8***
438 *for comparison. (C.) Estimates and Wald-type 95% confidence intervals of bidirectional causal*
439 *effects between current smoking and DNA methylation in the three MR-DoC models. In panels A*
440 *and C, the Y-axis labels indicate the CpG probe IDs and the respective genes in which the CpGs*
441 *are located.*

442 *Note. The numerical data underlying these plots are in **Supplementary Tables S1-S4.***

443

444 —

445

446 **DNAm loci potentially influenced by smoking are enriched for biological**
447 **processes relevant to smoking's adverse health outcomes**

448 In follow-up functional enrichment analyses, we identified 525 CpGs with potential *Current*
449 *Smoking* → *DNAm* effects (excluding 21 sites in the MHC region), based on consistent,
450 nominally significant estimates in all models (**Supplementary Table S1**). The mapped genes
451 showed extensive significant enrichment (FDR <0.05) for ontology clusters, including
452 hemopoiesis, cell morphogenesis, inflammatory response, regulation of cell differentiation, and
453 regulation of nervous system development, underscoring DNAm's potential role in the adverse
454 health sequelae of smoking (**Supplementary Figures S10-S12; Tables S5-S6**). In the *eFORGE*
455 analyses, these sites were significantly enriched (FDR <0.05) for overlap with a wide range of
456 gene regulatory elements in most of the tissue/cell types in reference datasets, suggesting
457 pervasive functional consequences of smoking's effects on DNAm (**Supplementary Figures**
458 **S13-S15; Tables S7-S9**).


459 **CpGs with consistent effects on current smoking show enrichment for brain-**
460 **related gene regulatory elements**

461 We identified 64 CpGs with potential *DNAm* → *Current Smoking* effects (none in the MHC
462 region), as indicated by consistent, nominally significant estimates across models
463 (**Supplementary Figure S16**). Gene-set enrichment analyses revealed no significant functional
464 enrichment (FDR <0.05), likely due to too few loci (**Supplementary Figures S17-S18; Tables**
465 **S10-S11**). However, the *eFORGE* analyses, which use precise chromatin-based information for
466 each CpG, showed significant enrichment (FDR <0.05) for overlap with enhancers in the brain,
467 blood (primary B cells, hematopoietic stem cells), lung, and mesodermal embryonic stem cells
468 (**Supplementary Figures S19-S21; Tables S12-S14**). These CpGs also showed significant
469 enrichment for histone marks in multiple tissues/cell types (including the brain, blood, and lung),
470 though the overlap with DNase-I hotspots was not significantly enriched. The tissues/cell types
471 predicted to be relevant for DNAm's effects on smoking liability may be prioritised for follow-
472 up functional studies.

473
474 To further gauge the tissue-specificity of *eFORGE* enrichment, we performed iterative follow-up
475 analyses with the CpGs overlapping with tissue/cell types of interest (**Supplementary Figures**
476 **S22-S24; Tables S15-S17**). These analyses elucidated a subset of 17 CpGs with significant and
477 highly specific enrichment for enhancers and histone marks (H3K4me1 and H3K4me4) in the
478 brain (**Figure 5**), along with weaker enrichment for H3K4me1 in the adrenal gland and thymus.
479 Ten of the 17 sites also overlapped with DNase-I hotspots in the brain, though the enrichment
480 was not statistically significant (FDR = 0.08) (**Supplementary Figure S25, Table S20**). The

481 causal estimates and mapped genes of these 17 CpGs are shown in **Supplementary Figure S26**.
482 Four of these CpGs also had consistent estimates of current smoking’s effects on DNAm
483 (identified by the column “g1_nominal” in **Supplementary Table S4**): cg25612391
484 (*SLC25A42*), cg05424060 (*GNAII*), cg10590964 (near *KIAA2012*), and cg05877788 (*TP53I13*).
485 Furthermore, prior pre-clinical and clinical studies have implicated 14 of the 17 mapped genes,
486 including three with potential bidirectional effects, in behavioural or neurological traits,
487 including alcohol dependence (*OSBPL5*) [39], cocaine use (*SLCO5A1*) [40], anxiety (*CCDC92*)
488 [41], depression (*GNAII*) [42], encephalomyopathy and brain stress response (*SLC25A42*)
489 [43,44], and dementia/Alzheimer’s disease pathology (*SIAH3*, *SRM*, *TP53I13*) [45–47].
490
491 Similar follow-up analyses with the CpGs overlapping with enhancers in the lung (potentially
492 etiologically relevant tissue) and the primary B-cells in cord blood (the tissue type with the most
493 significant enrichment) showed enrichment across several tissue/cell types, suggesting non-
494 specificity of the overlap in these tissues (**Supplementary Figures S27-S32; Tables S21-S26**).
495 Furthermore, the 18 CpGs overlapping with enhancers in primary B cells mapped to 16 genes, of
496 which five have been previously associated with (any) blood cell counts, but only one with
497 lymphocyte count in GWAS [48]. Thus, the sites driving the enrichment for B cells had little
498 overlap with the known lymphocyte-count GWAS associations, indicating likely minimal
499 confounding by residual cell-composition effects [35]. By comparison, the 64 CpGs with
500 potential *DNAm* → *Current Smoking* effects annotated to 51 genes, of which 16 show GWAS
501 associations with (any) blood cell counts and only two with lymphocyte count.
502

eFORGE Analyses of the CpG Sites with Potential Effects of DNA Methylation on Current Smoking



503

504 *Figure 5. Among the CpGs with potential effects of blood DNA methylation on current smoking liability, iterative eFORGE*
 505 *analyses elucidated sites enriched for overlap with brain-related chromatin states and histone marks.*

506 *The first iteration of eFORGE examined the 64 CpGs with potential effects of blood DNA methylation on current smoking liability*
507 *(Supplementary Figure S15), revealing 21 CpGs enriched for overlap with enhancers in the brain (Supplementary Figure S18/Table*
508 *S12). In follow-up analyses restricted to these 21 CpGs (eFORGE iteration 2), all 21 probes were also enriched for the brain*
509 *H3K4me1 marks, while 17 of these probes overlapped with H3K4me3 marks in the brain (Supplementary Figure S22/Table S16). This*
510 *iteration also showed significant enrichment (FDR $q < 0.01$) for histone marks in other tissues, including small and large intestines,*
511 *adrenal gland, and thymus. So, to identify a subset of these CpGs with potentially more specific enrichment for brain-related*
512 *functional elements, we restricted further analyses to the 17 sites overlapping with the brain H3K4me3 marks (eFORGE iteration 3).*
513 *This figure shows that these 17 sites showed highly specific enrichment for enhancers and histone marks in the brain (**Supplementary***
514 ***Tables S18-S19**). Ten of these sites also overlapped with DNase-I hotspots in the brain (Supplementary Table S20).*
515

516 **Attenuated effects of former smoking on DNAm**

517 Similar analyses for former smoking showed relatively attenuated inflation factor (λ) in all
518 models. For instance, MR-DoC2 models fitted across the 11,124 smoking-associated CpGs had λ
519 = 1.11 for *Former Smoking* \rightarrow *DNAm*, and $\lambda = 0.99$ for *DNAm* \rightarrow *Former Smoking*, compared to
520 1.20 and 1.01, respectively, for current smoking. Note that these λ calculations were not
521 restricted to the former-smoking-associated CpGs to allow for a comparison with current
522 smoking.

523


524 Among the former-smoking-associated CpGs, only five sites showed robust evidence of former
525 smoking's effects on DNAm, with consistent, statistically significant (FDR <0.05) causal
526 estimates in all three models (**Supplementary Figure S33**). These CpGs include cg05575921 in
527 *AHRR*, cg05951221, cg01940273, and cg21566642 near *ALPPL2*, and cg06126421 near *HLA-*
528 *DRB5* gene (in the MHC region). The causal estimates at these sites are similar to those of
529 *current* smoking's effects on DNAm, with overlapping confidence intervals (**Figure 6**). Thus,
530 the limited reversibility of smoking's causal effects may underlie the persistent associations of
531 former smoking with DNAm at these sites [2]. For the reverse effects of DNAm on former
532 smoking, no CpG showed consistent (at least nominally significant) causal estimates across
533 models (**Supplementary Figure S34**). Nevertheless, of the three CpGs with robust evidence of
534 DNAm's effects on current smoking, two were among the former-smoking-associated CpGs and
535 had overlapping confidence intervals of DNAm's estimated effects on *former* and *current*
536 smoking (**Supplementary Figure S35**).

537

538

CpGs with Putative Effects of Former Smoking on DNA Methylation

Sites with FDR < 0.05 in All Three Models



539

540 **Figure 6. Putative causal effects of former smoking on blood DNA methylation.**

541 *Estimates and Wald-type 95% confidence intervals of the causal effects of the liability for former*
542 *(versus never) smoking and (residualised and standardised) DNA methylation beta-values in*
543 *each of the three MR-DoC models: bidirectional MR-DoC2, MR-DoC1 with horizontal*
544 *pleiotropic path, and MR-DoC1 with unique environmental confounding (rE). The*
545 *corresponding estimates for current (versus never) smoking are also shown with dashed lines.*
546 *The text labels on the left indicate the CpG probe IDs and the genes mapped by the CpGs.*
547 *Note. The data underlying these plots are in **Supplementary Tables S1 and S27**, indicated by the*
548 *column `gl_robust`.*

549

Discussion

550 The integrated MR and twin models suggest that the causal effects of cigarette smoking on blood
551 DNAm likely underlie many of the associations seen in EWAS. Compared to a handful of CpGs
552 causally linked with smoking in previous MR analyses, we found over 500 CpGs with consistent,
553 nominally significant effects of current smoking on DNAm. These loci show broad enrichment
554 for tissue types and functional pathways that implicate numerous well-established harmful health
555 outcomes of smoking, including cell- and neuro-development, carcinogenesis, and immune
556 regulation. The discovery of more extensive and novel causal effects may partly be attributable
557 to the study design's ability to estimate the causal influences of *current* smoking specifically,
558 given the considerable reversibility of most smoking-associated DNAm changes upon smoking
559 cessation. Consistently, most of the estimated effects of smoking on DNAm were no longer
560 significant in the analyses of former smoking. Additionally, several CpGs showed evidence of
561 reverse and possibly bidirectional effects of DNAm on smoking liability, with a subset of these
562 loci enriched for gene regulatory functional elements in the brain. The detection of reverse or
563 bidirectional causal effects of blood DNAm on smoking highlights the potential utility of blood
564 DNAm as a biomarker to monitor addiction or interventions.

565

566 Previous discordant-twin analyses in NTR found 13 CpGs with significant DNAm differences
567 between MZ twins discordant for current smoking [24], suggesting potential causality. In the
568 MR-DoC analyses, eight of the 13 CpGs showed robust evidence of current smoking's effects on
569 DNAm, while none showed reverse effects. Taken together, these findings further triangulate the
570 evidence for smoking's effects on DNAm at these sites. Prior summary-statistics-based MR
571 analyses in GoDMC found no evidence of causal effects of lifetime smoking on DNAm, or *vice*
572 *versa* [21]. Another study [10] applied a single MR method and found nominally significant
573 effects of lifetime smoking on DNAm at 11 CpGs from the Illumina MethylationEPIC array
574 [49], of which two (cg14580211, cg15212295) overlap with Illumina 450k array data used in the
575 current study. In our MR-DoC analyses, only cg14580211 showed replication in the form of
576 consistent negative causal estimates of current smoking on DNAm. Furthermore, the nine CpGs
577 with previously reported reverse effects of DNAm on lifetime smoking behaviour in a single MR
578 model [11] showed inconsistent estimates in the three MR-DoC models. Interestingly, two of
579 these CpGs (cg09099830 and cg24033122; both in gene *ITGAL*) showed consistent, nominally
580 significant effects of current smoking on DNAm, underscoring the need for further replication of
581 both prior and current findings.

582

583 Of the three loci with robust evidence of DNAm's effects on current smoking liability, two are
584 located in genes *GNG7* and *RGS3*, which are integral to G protein-coupled receptor (GPCR)
585 signalling, adding to the growing literature on GPCR signalling pathways' potential role in

586 behavioural and neuropsychiatric outcomes [50]. Specifically, differential expression of both
587 *GNG7* [51] and *RGS3* [52] has been associated with addiction-related phenotypes in model
588 organisms. The third CpG annotates to *SLC15A4*, which encodes a lysosomal peptide/histidine
589 transporter involved in antigen presentation and innate immune response [53], including in mast
590 cells [54]. Thus, DNAm variation at this locus may reflect individual differences in
591 immunological tolerance of cigarette smoke and, consequently, maintenance of smoking
592 behaviour. Interestingly, these CpGs were significantly associated with neither cannabis use [7]
593 nor alcohol consumption [6] in recent large-scale EWASs. However, these studies reported
594 DNAm associations conditional on cigarette smoking, making them unsuitable for gauging
595 whether the CpGs with putative effects on smoking liability are also associated with other
596 substances. This raises the question of whether cigarette smoking should always be used as a
597 covariate in EWAS. If so, it may be prudent to report supplementary EWAS results without
598 smoking as a covariate, as some CpGs may have reverse or bidirectional causal relationships
599 with smoking.

600
601 Several factors need to be considered when interpreting the above results. We analysed DNAm
602 from whole blood, but smoking's causal relationships with DNAm may differ between specific
603 blood cell types. The results may also vary in other peripheral tissues, like buccal cells [55], and
604 other tissues relevant to smoking, like the brain. Moreover, the highly variable predictive
605 strength of mQTL allelic scores across CpGs (incremental- R^2 range: 0.43-76.95%; median
606 4.61%) affected the power to detect causal effects of blood DNAm on smoking liability [38].
607 When considering similar model applications across different health traits, this impact on power
608 is relevant to both directions of causation, as the IV of other traits may not be as strong as the
609 smoking PRS. Additionally, the Illumina 450k microarray used in this study covers a small
610 fraction of genome-wide potential methylation sites. Moreover, many of the measured smoking-
611 associated CpGs lacked a "relevant" mQTL allelic score with F-statistic >10 (**Supplementary**
612 **Figure S36**), and so have yet to be tested for *DNAm* \rightarrow *Smoking* causal effects. Newer low-cost
613 sequencing technology [56] may facilitate further causal discovery in the future.

614
615 Like all MR studies, the current results depend on the validity of the IV assumptions [28], which
616 can be difficult to test. Here, we relied on the statistical significance and consistency of the
617 causal estimates across different MR-DoC model specifications to account for potential
618 assumption violations, particularly horizontal pleiotropy. Yet, we cannot rule out residual bias
619 due to violations of the assumptions underlying MR [28] and twin modelling [57]. Moreover,
620 current MR-DoC models estimated linear causal effects. However, since DNAm is constrained
621 within certain biologically plausible values, the impact of smoking on DNAm may depend on
622 *prior* DNAm. Further development of MR-DoC models with interaction or quadratic effects will

623 benefit the study of such non-linear causal effects. Finally, we examined causality using only
624 binary smoking-status variables, as the number of individuals endorsing current or former
625 smoking was too small to fit MR-DoC models to smoking quantity (e.g., cigarettes per day) or
626 time since quitting. Further research with larger samples is needed to examine such dose-
627 response causal relationships.

628
629 The current study included participants of European ancestry only. Although prior EWASs show
630 highly concordant associations across ancestries [2,58], examining the generalizability of causal
631 estimates in non-European populations is an essential objective for further research. As MR-DoC
632 models estimate causal effects specific to the target dataset, rather than the discovery GWAS
633 samples, future research may apply this study design to subpopulations of interest, e.g., stratified
634 by sex or age, provided the population-wide GWAS results generalise adequately. Future
635 applications of MR-DoC analyses to DNAm data may also extend the current work to other traits
636 that show robust associations with DNAm [59] and have strong genetic IVs.

637
638 In conclusion, the inability to establish causality is a clear limitation of EWAS based on
639 surrogate tissues such as blood. Here, we applied the MR-DoC designs to examine the causality
640 between cigarette smoking and blood DNAm. The results suggest that many of the EWAS
641 associations are likely driven by the causal effects of current smoking on DNAm, and provide
642 evidence for reverse and potentially bidirectional causal relationships at some sites.

643 Underscoring the continuing value of twin studies for health and behaviour [60], our study
644 highlights the value of integrating DNAm, phenotypic information, and genetic data in twin
645 studies to uncover causal relationships of peripheral blood DNAm with complex traits. This
646 study design might be valuable for detecting causal epigenetic biomarkers of mental health in
647 general.

648

649

References



650

- 651 1. Wei S, Tao J, Xu J, Chen X, Wang Z, Zhang N, et al. Ten Years of EWAS. *Adv Sci*. 2021
652 Oct 1;8(20):2100727.
- 653 2. Joehanes R, Just AC, Marioni R, Pilling L, Reynolds L, Mandaviya PR, et al. Epigenetic
654 Signatures of Cigarette Smoking. *Circ Cardiovasc Genet*. 2016;9(5):436–47.
- 655 3. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian
656 randomization: using genes as instruments for making causal inferences in epidemiology.
657 *Stat Med*. 2008 Apr 15;27(8):1133–63.
- 658 4. Zillich L, Poisel E, Streit F, Frank J, Fries GR, Foo JC, et al. Epigenetic Signatures of
659 Smoking in Five Brain Regions. *J Pers Med*. 2022;12(4):566.
- 660 5. Hannon E, Dempster E, Viana J, Burrage J, Smith AR, Macdonald R, et al. An integrated
661 genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic
662 associations and differential DNA methylation. *Genome Biol*. 2016 Aug 30;17(1):176.
- 663 6. Dugué PA, Wilson R, Lehne B, Jayasekara H, Wang X, Jung CH, et al. Alcohol
664 consumption is associated with widespread changes in blood DNA methylation: Analysis of
665 cross-sectional and longitudinal data. *Addict Biol*. 2021 Jan 1;26(1):e12855.
- 666 7. Nannini DR, Zheng Y, Joyce BT, Kim K, Gao T, Wang J, et al. Genome-wide DNA
667 methylation association study of recent and cumulative marijuana use in middle aged
668 adults. *Mol Psychiatry* [Internet]. 2023 May 31; Available from:
669 <https://doi.org/10.1038/s41380-023-02106-y>
- 670 8. Dhana K, Braun KVE, Nano J, Voortman T, Demerath EW, Guan W, et al. An Epigenome-
671 Wide Association Study of Obesity-Related Traits. *Am J Epidemiol*. 2018 Aug
672 1;187(8):1662–9.
- 673 9. Davey Smith G, Ebrahim S. Mendelian randomization: Can genetic epidemiology
674 contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 2003
675 Feb;32(1):1–22.
- 676 10. Sun YQ, Richmond RC, Suderman M, Min JL, Battram T, Flatberg A, et al. Assessing the
677 role of genome-wide DNA methylation between smoking and risk of lung cancer using
678 repeated measurements: the HUNT study. *Int J Epidemiol*. 2021;50(5):1482–97.
- 679 11. Jamieson E, Korologou-Linden R, Wootton RE, Guyatt AL, Battram T, Burrows K, et al.
680 Smoking, DNA Methylation, and Lung Function: A Mendelian Randomization Analysis to
681 Investigate Causal Pathways. *Am J Hum Genet*. 2020 Mar 5;106(3):315–26.
- 682 12. Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak
683 instruments in Mendelian randomization studies. *Int J Epidemiol*. 2011 Jun;40(3):755–64.
- 684 13. Dugué PA, Jung CH, Joo JE, Wang X, Wong EM, Makalic E, et al. Smoking and blood
685 DNA methylation: an epigenome-wide association study and assessment of reversibility.
686 *Epigenetics*. 2020 Apr 2;15(4):358–68.
- 687 14. Heath AC, Kessler RC, Neale MC, Hewitt JK, Eaves LJ, Kendler KS. Testing hypotheses
688 about direction of causation using cross-sectional family data. *Behav Genet*. 1993 Jan
689 1;23(1):29–50.
- 690 15. Minică CC, Dolan CV, Boomsma DI, De Geus E, Neale MC. Extending Causality Tests
691 with Genetic Instruments: An Integration of Mendelian Randomization with the Classical
692 Twin Design. *Behav Genet*. 2018;48(4):337–49.
- 693 16. Castro-de-Araujo LFS, Singh M, Zhou Y, Vinh P, Verhulst B, Dolan CV, et al. MR-DoC2:

- 694 Bidirectional Causal Modeling with Instrumental Variables and Data from Relatives. *Behav*
695 *Genet.* 2023 Feb 1;53(1):63–73.
- 696 17. Minică CC, Boomsma DI, Dolan CV, De Geus E, Neale MC. Empirical comparisons of
697 multiple Mendelian randomization approaches in the presence of assortative mating. *Int J*
698 *Epidemiol.* 2020 Aug 1;49(4):1185–93.
- 699 18. Ligthart L, van Beijsterveldt CEM, Kevenaar ST, de Zeeuw E, van Bergen E, Bruins S, et
700 al. The Netherlands Twin Register: Longitudinal Research Based on Twin and Twin-
701 Family Designs. *Twin Res Hum Genet.* 2019;22(6):623–36.
- 702 19. Willemsen G, de Geus EJC, Bartels M, van Beijsterveldt CEMT, Brooks AI, Estourgie-van
703 Burk GF, et al. The Netherlands Twin Register Biobank: A Resource for Genetic
704 Epidemiological Studies. *Twin Res Hum Genet.* 2012/02/21 ed. 2010;13(3):231–45.
- 705 20. Singh M, Verhulst B, Vinh P, Zhou Y (Daniel), Castro-de-Araujo LFS, Hottenga JJ, et al.
706 Using Instrumental Variables to Measure Causation over Time in Cross-Lagged Panel
707 Models. *Multivar Behav Res.* 2024 Feb 15;59(2):342–70.
- 708 21. Min JL, Hemani G, Hannon E, Dekkers KF, Castillo-Fernandez J, Luijk R, et al. Genomic
709 and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nat Genet.*
710 2021 Sep 1;53(9):1311–21.
- 711 22. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA
712 methylation array with single CpG site resolution. *New Genomic Technol Appl.* 2011 Oct
713 1;98(4):288–95.
- 714 23. van Dongen J, Nivard MG, Willemsen G, Hottenga JJ, Helmer Q, Dolan CV, et al. Genetic
715 and environmental influences interact with age and sex in shaping the human methylome.
716 *Nat Commun.* 2016 Sep 1;7(1):11115.
- 717 24. van Dongen J, Willemsen G, BIOS Consortium, de Geus EJ, Boomsma DI, Neale MC.
718 Effects of smoking on genome-wide DNA methylation profiles: A study of discordant and
719 concordant monozygotic twin pairs. Aldrich M, Rathmell WK, Aldrich M, Craig J, Kaprio
720 J, editors. *eLife.* 2023 Aug 10;12:e83286.
- 721 25. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
722 PLINK: rising to the challenge of larger and richer datasets. *GigaScience.* 2015 Dec 1;4(1).
- 723 26. Vilhjálmsson J, Yang J, Finucane K, Gusev A, Lindström S, Ripke S, et al. Modeling
724 Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. *Am J Hum Genet.*
725 2015 Oct 1;97(4):576–92.
- 726 27. Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels
727 gene discovery for tobacco and alcohol use. *Nature.* 2022 Dec 22;612(7941):720–4.
- 728 28. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. *Cold*
729 *Spring Harb Perspect Med.* 2022 Jan 1;12(1):a040501.
- 730 29. Neale MC, Hunter MD, Pritikin JN, Zahery M, Brick TR, Kirkpatrick RM, et al. OpenMx
731 2.0: Extended Structural Equation and Statistical Modeling. *Psychometrika.*
732 2016;81(2):535–49.
- 733 30. Verhulst B, Neale MC. Best Practices for Binary and Ordinal Data Analyses. *Behav Genet.*
734 2021;51(3):204–14.
- 735 31. van Iterson M, van Zwet EW, Heijmans BT, the BIOS Consortium. Controlling bias and
736 inflation in epigenome- and transcriptome-wide association studies using the empirical null
737 distribution. *Genome Biol.* 2017 Jan 27;18(1):19.
- 738 32. Gogarten SM, Bhangale T, Conomos MP, Laurie CA, McHugh CP, Painter I, et al.
739 GWASTools: an R/Bioconductor package for quality control and analysis of genome-wide

- 740 association studies. *Bioinformatics*. 2012 Dec 1;28(24):3329–31.
- 741 33. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
742 Approach to Multiple Testing. *J R Stat Soc Ser B Methodol*. 1995 Jan 1;57(1):289–300.
- 743 34. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape
744 provides a biologist-oriented resource for the analysis of systems-level datasets. *Nat*
745 *Commun*. 2019 Apr 3;10(1).
- 746 35. Breeze CE, Paul DS, van Dongen J, Butcher LM, Ambrose JC, Barrett JE, et al. eFORGE:
747 A Tool for Identifying Cell Type-Specific Signal in Epigenomic Data. *Cell Rep*. 2016 Nov
748 15;17(8):2137–50.
- 749 36. Breeze CE, Reynolds AP, van Dongen J, Dunham I, Lazar J, Neph S, et al. eFORGE v2.0:
750 updated analysis of cell type-specific signal in epigenomic data. *Bioinformatics*. 2019 Nov
751 15;35(22):4767–9.
- 752 37. Breeze CE. Cell Type-Specific Signal Analysis in Epigenome-Wide Association Studies.
753 In: Guan W, editor. *Epigenome-Wide Association Studies: Methods and Protocols*
754 [Internet]. New York, NY: Springer US; 2022. p. 57–71. Available from:
755 https://doi.org/10.1007/978-1-0716-1994-0_5
- 756 38. Castro-de-Araujo LF, Singh M, Zhou Y, Vinh P, Maes HH, Verhulst B, et al. Power,
757 measurement error, and pleiotropy robustness in twin-design extensions to Mendelian
758 Randomization. *Research square*. United States; 2023. p. rs.3.rs-3411642.
- 759 39. Edenberg HJ, Koller DL, Xuei X, Wetherill L, McClintick JN, Almasy L, et al. Genome-
760 Wide Association Study of Alcohol Dependence Implicates a Region on Chromosome 11.
761 *Alcohol Clin Exp Res*. 2010 May 1;34(5):840–52.
- 762 40. Khan AH, Bagley JR, LaPierre N, Gonzalez-Figueroa C, Spencer TC, Choudhury M, et al.
763 Genetic pathways regulating the longitudinal acquisition of cocaine self-administration in a
764 panel of inbred and recombinant inbred mice. *Cell Rep*. 2023 Aug 29;42(8):112856.
- 765 41. Jin X, Dong S, Yang Y, Bao G, Ma H. Nominating novel proteins for anxiety via
766 integrating human brain proteomes and genome-wide association study. *J Affect Disord*.
767 2024 Aug 1;358:129–37.
- 768 42. Sarkar A, Chachra P, Kennedy P, Pena CJ, Desouza LA, Nestler EJ, et al. Hippocampal
769 HDAC4 Contributes to Postnatal Fluoxetine-Evoked Depression-Like Behavior.
770 *Neuropsychopharmacology*. 2014 Aug 1;39(9):2221–32.
- 771 43. Aldosary M, Baselm S, Abdulrahim M, Almass R, Alsagob M, AlMasseri Z, et al.
772 SLC25A42-associated mitochondrial encephalomyopathy: Report of additional founder
773 cases and functional characterization of a novel deletion. *JIMD Rep*. 2021 Jul 1;60(1):75–
774 87.
- 775 44. Stankiewicz AM, Jaszczyk A, Goscik J, Juszcak GR. Stress and the brain transcriptome:
776 Identifying commonalities and clusters in standardized data from published experiments.
777 *Prog Neuropsychopharmacol Biol Psychiatry*. 2022 Dec 20;119:110558.
- 778 45. Cochran JN, Acosta-Urbe J, Esposito BT, Madrigal L, Aguillón D, Giraldo MM, et al.
779 Genetic associations with age at dementia onset in the PSEN1 E280A Colombian kindred.
780 *Alzheimers Dement*. 2023 Sep 1;19(9):3835–47.
- 781 46. Mahajan UV, Varma VR, Griswold ME, Blackshear CT, An Y, Oommen AM, et al.
782 Dysregulation of multiple metabolic networks related to brain transmethylation and
783 polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic
784 study. *PLOS Med*. 2020 Jan 24;17(1):e1003012.
- 785 47. Blanco-Luquin I, Acha B, Urdánoz-Casado A, Sánchez-Ruiz De Gordo J, Vicuña-Urriza J,

- 786 Roldán M, et al. Early epigenetic changes of Alzheimer’s disease in the human
787 hippocampus. *Epigenetics*. 2020 Oct 2;15(10):1083–92.
- 788 48. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, et al. The Polygenic and
789 Monogenic Basis of Blood Traits and Diseases. *Cell*. 2020 Sep 3;182(5):1214-1231.e11.
- 790 49. Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, et al. Critical
791 evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA
792 methylation profiling. *Genome Biol*. 2016 Oct 7;17(1):208.
- 793 50. Wong TS, Li G, Li S, Gao W, Chen G, Gan S, et al. G protein-coupled receptors in
794 neurodegenerative diseases and psychiatric disorders. *Signal Transduct Target Ther*. 2023
795 May 3;8(1):177.
- 796 51. Stankiewicz AM, Goscik J, Dyr W, Juszcak GR, Ryglewicz D, Swiergiel AH, et al. Novel
797 candidate genes for alcoholism — transcriptomic analysis of prefrontal medial cortex,
798 hippocampus and nucleus accumbens of Warsaw alcohol-preferring and non-preferring rats.
799 *Pharmacol Biochem Behav*. 2015 Dec 1;139:27–38.
- 800 52. Burchett SA, Bannon MJ, Granneman JG. RGS mRNA Expression in Rat Striatum. *J*
801 *Neurochem*. 1999 Apr 1;72(4):1529–33.
- 802 53. Chen X, Xie M, Zhang S, Monguió-Tortajada M, Yin J, Liu C, et al. Structural basis for
803 recruitment of TASL by SLC15A4 in human endolysosomal TLR signaling. *Nat Commun*.
804 2023 Oct 20;14(1):6627.
- 805 54. Kobayashi T, Tsutsui H, Shimabukuro-Demoto S, Yoshida-Sugitani R, Karyu H,
806 Furuyama-Tanaka K, et al. Lysosome biogenesis regulated by the amino-acid transporter
807 SLC15A4 is critical for functional integrity of mast cells. *Int Immunol*. 2017 Dec
808 31;29(12):551–66.
- 809 55. Teschendorff AE, Yang Z, Wong A, Pipinikas CP, Jiao Y, Jones A, et al. Correlation of
810 Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation
811 Changes in Epithelial Cancer. *JAMA Oncol*. 2015 Jul 1;1(4):476–85.
- 812 56. Simpson JT, Workman RE, Zuzarte PC, David M, Dursi LJ, Timp W. Detecting DNA
813 cytosine methylation using nanopore sequencing. *Nat Methods*. 2017 Apr 1;14(4):407–10.
- 814 57. Evans DM, Gillespie NA, Martin NG. Biometrical genetics. *Biol Psychol*. 2002;61(1):33–
815 51.
- 816 58. Fang F, Quach B, Lawrence KG, van Dongen J, Marks JA, Lundgren S, et al. Trans-
817 ancestry epigenome-wide association meta-analysis of DNA methylation with lifetime
818 cannabis use. *Mol Psychiatry* [Internet]. 2023 Nov 7; Available from:
819 <https://doi.org/10.1038/s41380-023-02310-w>
- 820 59. Jin Z, Liu Y. DNA methylation in human diseases. *Genes Dis*. 2018 Mar 1;5(1):1–8.
- 821 60. Hagenbeek FA, Hirzinger JS, Breunig S, Bruins S, Kuznetsov DV, Schut K, et al.
822 Maximizing the value of twin studies in health and behaviour. *Nat Hum Behav*. 2023 Jun
823 1;7(6):849–60.
- 824



18,760 CpG sites associated with current versus never smoking (“smoking-associated”) and 2,568 CpG sites associated with former versus never smoking (“former-smoking-associated”) in an independent EWAS meta-analysis

Autosomal CpG sites passing the QC metrics in the Netherlands Twin Register

Smoking → DNAm (Unidirectional MR-DoC1)

16,940 (90.3%) smoking-associated CpG sites

2,330 (90.7%) former-smoking-associated CpG sites

13,275 smoking-associated CpG sites had mQTL summary statistics available from the Genetics of DNA Methylation Consortium (GoDMC). 12,940 of these sites had summary statistics for *cis*-mQTLs.


CpG sites filtered for mQTL allelic score with F-statistic >10

DNAm → Smoking (Unidirectional MR-DoC1) and Bidirectional MR-DoC2 models


11,124 (65.7%) smoking-associated CpG sites

1,782 (76.5%) former-smoking-associated CpG sites

Putative Causal Effects of Current Smoking on DNA Methylation in MR-DoC Models




Putative Causal Effects of Current Smoking on DNA Methylation FDR < 0.05



Causal Estimates


From MR-DoC1 Model with rE




Solid Points indicate the 64 sites significant at FDR < 0.05 in all three models
Labeled Points indicate the 14 sites significant after Bonferroni correction in more than one model

A. Causal Estimates of DNAm's Effects on Current Smoking


CpGs with FDR < 0.05 in All Three Models




Intersection size



B. Putative Effects of DNA Methylation on Current Smoking
FDR < 0.05



C. Suggestive Bidirectional Causal Effects between Current Smoking and Blood DNA Methylation



medRxiv preprint doi: <https://doi.org/10.1101/2024.06.19.24309184>; this version posted November 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

eFORGE Analyses of the CpG Sites with Potential Effects of DNA Methylation on Current Smoking

64 CpG sites with potential effects of DNA methylation on current smoking


eFORGE Iteration 1

21 CpG sites enriched for overlap with Enhancers in the Fetal Brain samples

eFORGE Iteration 2

17 CpG sites enriched for overlap with H3K4me3 in the Fetal Brain samples

eFORGE Iteration 3



CPGs with Putative Effects of Former Smoking on DNA Methylation

Sites with FDR < 0.05 in All Three Models

